Synchronous Hodgkin Lymphoma and Papillary Thyroid Carcinoma: The Importance of Positron Emission Tomography/Computed Tomography (PET/CT)

J Clin Exp Invest 2019;10(1):em00722.

https://doi.org/10.5799/jcei/5761

OPEN ACCESS

Download Full Text (PDF)

Abstract

We report a 50-year-old male with synchronous Hodgkin lymphoma (HL) and papillary thyroid carcinoma (PTC). The patient was diagnosed as having HL of the nodular sclerosis type on excisional biopsy of an enlarged right scalene node in March 2018. After further examinations including bone marrow biopsy and positron emission tomography/computed tomography (PET/CT) with 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG), he was classified as having stage IVA HL with bone marrow involvement. The patient’s medical history was unremarkable for any chronic disease or previous throid disease. He had no history of irradiation to head and neck, nor had any regular medications. Her mother had a diagnosis of breast carcinoma.

References

  • Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325:599-605.
  • Abboud B, Yazbeck T, Daher R, Chahine G, Ghorra C. Papillary thyroid carcinoma after chemotherapy for Hodgkin's disease. Am Surg. 2010;76:1316-7.
  • Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012;97:3866-75.

Citation

Uz B. Synchronous Hodgkin Lymphoma and Papillary Thyroid Carcinoma: The Importance of Positron Emission Tomography/Computed Tomography (PET/CT). J Clin Exp Invest. 2019;10(1):em00722. https://doi.org/10.5799/jcei/5761